Biobanking Equipment Annual Sales, Size, Major Strategies, Key Companies, Revenue Share Analysis, 2018-2026

                                                                BioBanking Equipment

Biobanking Equipment refers to organized collections of biological samples and related data that are kept for use in future research. Blood, tissue, and urine are common bio specimens handled by bio banks. They are founded either as independent entities or as part of university medical or research institutes, pharmaceutical or biotechnology firms. Blood, enzymes, organ tissue, urine, and DNA, RNA, and cell lines are just a few examples of the samples that can be found in bio banks, which can also be disease- or population-based.

As part of precision medicine, the bio banks also assist in the development of a number of novel medicines that are specifically adapted to a patient's unique genetic makeup or tumor's unique genetic profile. Alzheimer's disease, arthritis, cardiovascular illnesses, diabetes, cancer, and psychiatric disorders can all be successfully treated with precision medicine. Obesity, neurological disease, and pain

In 2017, the market for BioBanking Equipment was valued at US$ 1,778.3 million, and it is anticipated to grow at a strong CAGR of 7.5% over the following five years (2018 – 2026).

Biobanking Equipment- The process of preserving bodily fluids or tissues for use in research to better understand health and illness is known as biobanking. The most popular types of samples kept for future investigation are blood and urine. Saliva, fat samples, umbilical cord blood, and spinal fluid are also taken for various tests. The growth of government and private financing initiatives for research is a key factor propelling the worldwide biobanking equipment market. An increase in chronic disease cases also spurs market expansion. In the recent years, North America has experienced substantial expansion. For hosting a significant number of drug discovery and research operations in these two areas, several bioscience businesses establish headquarters and research facilities there. However, hefty automation costs and moral and social In these regions, market expansion is anticipated to be hampered in the near future by problems with the acquisition of bio specimen samples.

Segmentation for biobanking Equipment

The specimen type, kind of bio bank, ownership, application, end user, and area are the several market segments for bio banking. The market is divided into cell lines, nucleic acid, solid tissue, blood products, and other specimen types. The market is divided into population-based bio banks and disease-focused bio banks based on the type of bio bank. It is broken down into national/regional agencies, non-profit organizations, universities, and private organizations according to ownership. The study's applications include both research and therapeutic ones.

Key player

v   Merck KGaA

v  Chart Industries Inc.

v  Greiner Holding AG

v  Hamilton Company

v  Brooks Automation Inc.

v  Panasonic Healthcare Holdings